What Is VNS in Neurology? How Vagus Nerve Stimulation Works

Vagus nerve stimulation, commonly abbreviated VNS, is a form of neuromodulation that sends mild electrical pulses to the vagus nerve to alter brain activity. It is FDA-approved for drug-resistant epilepsy and treatment-resistant depression, and more recently cleared for post-stroke upper-limb rehabilitation. The therapy works by tapping into the vagus nerve’s role as a superhighway between the body and the brain, influencing everything from seizure networks to mood-regulating circuits to the immune system. What began as a niche surgical intervention in the late 1990s has grown into a versatile platform that researchers are now testing against conditions from Alzheimer’s disease to traumatic brain injury.

What the Vagus Nerve Actually Does

The vagus nerve is the longest cranial nerve in the body, running from the brainstem down through the neck, chest, and abdomen. About 80 percent of its fibers carry sensory information upward to the brain, while the rest send motor and parasympathetic signals downward to organs like the heart, lungs, and gut. It regulates heart rate, digestion, breathing, and inflammatory responses, essentially acting as the body’s main line of communication between the central nervous system and the visceral organs.

VNS exploits the upward-traveling sensory fibers. A small electrical pulse applied to the nerve in the neck rides those fibers into the brainstem, specifically to a relay station called the nucleus of the solitary tract. From there, the signal fans out to regions involved in seizure control, mood, arousal, and autonomic regulation. Research in animal models shows that even mild stimulation at standard therapeutic intensities activates these brainstem neurons, but that the full downstream effect depends on feedback loops running back down from higher brain regions to amplify the initial signal.¹ In other words, VNS does not just ring a doorbell at the brainstem; it sets off a cascade that recruits circuits across the brain.

How VNS Changes Brain Activity

VNS affects the brain through several overlapping mechanisms. It modulates the release of key neurotransmitters including norepinephrine, serotonin, and acetylcholine, chemicals deeply involved in mood, alertness, and seizure threshold. It also promotes neural plasticity, helps maintain the integrity of the blood-brain barrier, and has anti-inflammatory effects that extend throughout the body.²

One mechanism that has attracted particular attention is cortical desynchronization. In epilepsy, seizures involve abnormal, synchronized electrical firing across brain networks. Studies in patients who have both a VNS device and an implanted brain-recording device show that when VNS is actively stimulating, it disrupts that pathological synchrony, especially in the theta and beta frequency bands.³ Separate work has statistically linked the degree of this desynchronization to how well a patient responds to VNS, lending further support to the idea that breaking up abnormal brain rhythms is central to how the therapy fights seizures.⁴

Beyond the brain, the vagus nerve controls what researchers call the cholinergic anti-inflammatory pathway. The efferent (outgoing) branch of the vagus nerve releases acetylcholine, which acts on receptors on immune cells like macrophages, dialing down the production of pro-inflammatory molecules.⁵ This pathway protects against systemic inflammation and has fueled research into VNS for autoimmune and inflammatory disorders like rheumatoid arthritis and Crohn’s disease.⁶

Epilepsy, the Original Indication

VNS was first approved for epilepsy in 1997 in the United States, and it remains the most established use. It is reserved for people with drug-resistant epilepsy, meaning seizures that persist despite trials of two or more appropriate medications. The device is not a cure. The goal is seizure reduction rather than elimination, and the benefits tend to build over months to years.

In randomized controlled trials, VNS has produced a 50 percent or greater reduction in seizure frequency in roughly a quarter to two-fifths of patients within the first year.⁷ Longer follow-up tends to show higher response rates. A study tracking adult patients over several years found that about two-thirds eventually experienced meaningful improvements in seizure frequency, duration, or intensity.⁸ This progressive improvement is a hallmark of VNS and distinguishes it from many medications, whose effect is typically maximal early on and may fade with time.

Newer VNS generators can also detect sudden increases in heart rate, a common early sign that a seizure is starting, and automatically deliver an extra burst of stimulation. This responsive mode adds a layer of on-demand intervention on top of the device’s regular scheduled cycles.⁹ Studies suggest that switching from traditional scheduled stimulation to this tachycardia-responsive mode provides additional seizure reduction.¹⁰

VNS in Children With Epilepsy

Children can receive VNS as well, and it is sometimes considered even for very young patients. In a study of children aged six and under, the response rate (at least half their seizures eliminated) was about 55 percent at one year and 60 percent at two years.¹¹ A systematic review and meta-analysis pooling data across pediatric studies concluded that VNS shows possible effectiveness in children with drug-resistant epilepsy, though complete seizure freedom remains uncommon.¹²

A multicenter study in China followed pediatric patients after implantation and found that about one in five to one in four achieved at least a 50 percent seizure reduction within the first six months, with adverse events being mild and transient.¹³ The lower early response rates compared with longer-term data from other studies reinforce the pattern seen in adults: VNS tends to work better the longer it is in place. Families considering it should expect a slow ramp rather than an overnight improvement.

Treatment-Resistant Depression

The mood-related effects of VNS were noticed during early epilepsy trials, when some patients reported improved mood independent of seizure control. This led to a separate FDA approval for treatment-resistant depression in 2005. The evidence here is more nuanced than in epilepsy, partly because the pivotal short-term trial did not clearly separate VNS from sham stimulation. The stronger evidence comes from longer observation.

A five-year observational registry compared patients receiving VNS plus standard care to those receiving standard care alone. The VNS group had a cumulative response rate of about 68 percent, compared with roughly 41 percent in the standard-care group. Remission rates showed a similar gap, with about 43 percent of VNS patients achieving remission at least once versus about 26 percent of controls.¹⁴ A smaller long-term follow-up reported that all three patients with different subtypes of treatment-resistant depression achieved clinical remission within two years of VNS implantation.¹⁵

Animal imaging research helps explain the neural basis for these mood effects. Functional brain imaging in rats during VNS showed that stimulation reorganized connectivity within the limbic system, the brain’s emotional processing network. The hippocampus formed stronger internal connections, while the cingulate cortex, a region tied to rumination and negative mood, became less correlated with the reward-related ventral striatum.¹⁶ These are exactly the kinds of circuit shifts you would want to see in a treatment for depression, and they echo changes seen with effective antidepressant medications.

Stroke Rehabilitation and Paired VNS

One of the most exciting newer applications of VNS is in stroke recovery, specifically for people who have lasting arm weakness after an ischemic stroke. The idea is different from epilepsy or depression: here, VNS is paired with physical rehabilitation exercises in real time. Each time a patient performs a movement, the therapist triggers a brief VNS pulse. The theory is that the burst of neuromodulators released by VNS, especially norepinephrine and acetylcholine, opens a window of heightened plasticity in the motor cortex, helping the brain rewire around the damaged area.

A pivotal Phase III trial demonstrated that VNS paired with rehab led to greater improvement in upper-limb function than rehab alone. After six weeks of in-clinic therapy plus 90 days of home exercises, the VNS group gained about three more points on a standard arm-function scale than the control group. Roughly half of VNS patients achieved a clinically meaningful improvement of six or more points, compared with about a quarter of those who received rehab alone.¹⁷ A subgroup analysis from the same trial confirmed these between-group differences early in the treatment course.¹⁸

Timing and intensity matter. Animal research has shown that standard-intensity VNS paired with a motor task roughly doubled the brain’s cortical representation of the trained movement compared to the same training without VNS. But overly intense or poorly timed stimulation wiped out the benefit entirely, producing no more plasticity than sham treatment.¹⁹ This is one reason VNS for stroke rehab requires careful clinical protocols rather than a “more is better” approach.

Non-Invasive VNS

Traditional VNS requires surgery: a pulse generator about the size of a stopwatch is implanted under the skin below the collarbone, with a wire threaded up to the left vagus nerve in the neck. The procedure takes about an hour and carries typical surgical risks, plus device-specific complications. Non-invasive alternatives have emerged to sidestep surgery entirely.

There are two main non-invasive approaches. One delivers stimulation through the skin of the neck over the vagus nerve using a handheld device. The other targets the ear, specifically the tragus (the small cartilage flap at the ear canal’s opening), where a branch of the vagus nerve surfaces close to the skin. Imaging studies confirm that stimulating the tragus activates the same central vagal pathways as implanted VNS.²⁰

The cervical (neck) non-invasive device has been most studied for headache disorders. A meta-analysis found that it is effective for acute pain relief in both migraine and cluster headache.²¹ In a randomized trial of chronic cluster headache, adding non-invasive VNS to standard care reduced attacks by about four more per week than standard care alone, and 40 percent of VNS patients achieved at least a 50 percent reduction in attacks, versus about 8 percent of controls.²² A health technology assessment has also evaluated its cost-effectiveness for cluster headache and migraine prevention and acute treatment.²³

Non-invasive devices improve the safety and accessibility of VNS considerably. They eliminate surgical risks and let patients self-administer treatment on demand.²⁴ The trade-off is that non-invasive stimulation is generally less precise and less intense than an implanted electrode directly on the nerve, which is why most epilepsy and depression protocols still use implanted devices.

Side Effects and Safety Profile

For implanted VNS, the most common side effects are tied to the stimulation cycle itself. Voice changes or hoarseness top the list, affecting roughly 45 percent of patients in a large meta-analysis. Tingling sensations (about 16 percent), cough (15 percent), shortness of breath during stimulation (about 14 percent), and pain at the implant site (about 12 percent) round out the most frequent complaints.²⁵ These effects generally occur during the “on” phase of stimulation and often improve when stimulus intensity is lowered.²⁶

Serious complications are uncommon. Infection at the surgical site is the most concerning implantation-related risk. Rare events during surgery include brief slowing of the heart rate or vocal cord weakness, which typically resolves within months.²⁷ In the grand scheme of neurological implant surgeries, VNS has a relatively benign safety record. The device does require battery replacement every several years (newer models last longer), which means a minor outpatient procedure to swap the generator.

Effects on the Heart and Autonomic Nervous System

Because the vagus nerve directly innervates the heart, any form of VNS raises natural questions about cardiac safety. The vagus is the main brake on heart rate; stimulating it pushes the autonomic balance toward the parasympathetic, “rest and digest” side. In healthy use, this is generally considered beneficial. Heart rate variability, a marker of healthy autonomic function, tends to increase during VNS, reflecting that shift toward parasympathetic predominance.²⁸

One study found that VNS affected heart rate variability differently depending on whether the patient was asleep or awake, increasing complexity during sleep and decreasing it during wakefulness.²⁹ Researchers have also identified VNS as a potential therapy for cardiovascular conditions like heart failure and recovery after heart attack, precisely because it can recalibrate autonomic tone. Some of this work remains preclinical, but the cardiac link is one reason VNS keeps appearing in cardiovascular research as well as neurology.³⁰

Emerging Research Frontiers

Beyond the approved indications, VNS is being explored for conditions that are still firmly in the experimental stage. In animal models of traumatic brain injury, VNS has restored deficits in coordination, balance, and cognitive function, with proposed mechanisms including neuroprotection and repair of disrupted neural circuits.³¹

Alzheimer’s disease and related dementias represent another frontier. A recent preclinical study found that perioperative VNS in mice with Alzheimer’s-like pathology reduced amyloid plaque burden and neuronal loss, and improved the activity of specialized immune cells in the brain called microglia that help clear toxic protein deposits.³² These are mouse results, and the leap to human benefit is never guaranteed, but the anti-inflammatory and neuroprotective properties of VNS make it a plausible candidate for neurodegenerative disease research.

The broader pattern across these experimental applications is consistent: VNS appears to create a neurochemical environment in the brain that favors repair and adaptation. Whether that translates from lab bench to clinic for each condition remains an open question, but the versatility of the vagus nerve as a therapeutic target is why VNS research has expanded so rapidly across neurology and well beyond it.

A Brief History of the Idea

The concept of electrically stimulating the vagus nerve to treat neurological conditions is older than most people realize. In the 1880s, an American neurologist named James Leonard Corning experimented with transcutaneous electrical stimulation of the vagus nerve combined with carotid artery compression, aiming to reduce cerebral blood flow and stop seizures.³³ The approach was not widely adopted and was eventually abandoned. It took another century before animal studies in the 1980s revived the idea, leading to the first human implant trials in the late 1980s and FDA approval a decade later. That long arc from 19th-century experimentation to modern approval underscores both how unconventional the therapy seemed for most of medical history and how much the field’s understanding of the vagus nerve’s role had to mature before VNS could be taken seriously.